Cargando…

In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis

Cardiac remodelling following myocardial infarction (MI) is a maladaptive change associated with progressive heart failure and compromises long‐term clinical outcome. A substantial proportion of patients afflicted by MI still develop adverse outcomes associated with cardiac remodelling. Therefore, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Shuai, Liang, Yubin, Chen, Peipei, Zhang, Yuzhuo, Yin, Xin, Zhang, Minzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520298/
https://www.ncbi.nlm.nih.gov/pubmed/32701210
http://dx.doi.org/10.1111/jcmm.15611
_version_ 1783587756718424064
author Mao, Shuai
Liang, Yubin
Chen, Peipei
Zhang, Yuzhuo
Yin, Xin
Zhang, Minzhou
author_facet Mao, Shuai
Liang, Yubin
Chen, Peipei
Zhang, Yuzhuo
Yin, Xin
Zhang, Minzhou
author_sort Mao, Shuai
collection PubMed
description Cardiac remodelling following myocardial infarction (MI) is a maladaptive change associated with progressive heart failure and compromises long‐term clinical outcome. A substantial proportion of patients afflicted by MI still develop adverse outcomes associated with cardiac remodelling. Therefore, it is crucial to identify biomarkers for the early prediction of cardiac remodelling. An in‐depth proteomics approach, including both semi‐quantitative and quantitative antibody arrays, was used to identify circulating biomarkers that may be associated with detrimental cardiac remodelling. Furthermore, statistical correlation analysis was performed between the candidate biomarkers and clinical cardiac remodelling data to demonstrate their clinical utility. A systematic proteomics approach revealed that sclerostin (SOST), growth differentiation factor‐15 (GDF‐15), urokinase‐type plasminogen activator (uPA), and midkine (MK) were increased, while monocyte chemotactic protein‐3 (MCP‐3) was uniquely decreased in MI patients who developed cardiac remodelling, compared to MI patients who did not develop cardiac remodelling and healthy humen. Moreover, correlation analyses between serum proteomes and cardiac remodelling echocardiographic parameters demonstrated a moderate positive association between left ventricular end‐diastolic volume index (LVEDVi) and the three serum proteins, uPA, MK and GDF‐15 (P < .05, respectively), and a moderate negative correlation between LV ejection fraction (LVEF) and these serum proteins (P < .05, respectively). Importantly, uPA and MK were firstly identified to be associated with the development of cardiac remodelling. The present study contributes to a better understanding of the various cytokines expressed during adverse cardiac remodelling. The identified biomarkers may facilitate early identification of patients at high risk of ischaemic heart failure pending further confirmation through larger clinical trials.
format Online
Article
Text
id pubmed-7520298
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75202982020-09-30 In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis Mao, Shuai Liang, Yubin Chen, Peipei Zhang, Yuzhuo Yin, Xin Zhang, Minzhou J Cell Mol Med Original Articles Cardiac remodelling following myocardial infarction (MI) is a maladaptive change associated with progressive heart failure and compromises long‐term clinical outcome. A substantial proportion of patients afflicted by MI still develop adverse outcomes associated with cardiac remodelling. Therefore, it is crucial to identify biomarkers for the early prediction of cardiac remodelling. An in‐depth proteomics approach, including both semi‐quantitative and quantitative antibody arrays, was used to identify circulating biomarkers that may be associated with detrimental cardiac remodelling. Furthermore, statistical correlation analysis was performed between the candidate biomarkers and clinical cardiac remodelling data to demonstrate their clinical utility. A systematic proteomics approach revealed that sclerostin (SOST), growth differentiation factor‐15 (GDF‐15), urokinase‐type plasminogen activator (uPA), and midkine (MK) were increased, while monocyte chemotactic protein‐3 (MCP‐3) was uniquely decreased in MI patients who developed cardiac remodelling, compared to MI patients who did not develop cardiac remodelling and healthy humen. Moreover, correlation analyses between serum proteomes and cardiac remodelling echocardiographic parameters demonstrated a moderate positive association between left ventricular end‐diastolic volume index (LVEDVi) and the three serum proteins, uPA, MK and GDF‐15 (P < .05, respectively), and a moderate negative correlation between LV ejection fraction (LVEF) and these serum proteins (P < .05, respectively). Importantly, uPA and MK were firstly identified to be associated with the development of cardiac remodelling. The present study contributes to a better understanding of the various cytokines expressed during adverse cardiac remodelling. The identified biomarkers may facilitate early identification of patients at high risk of ischaemic heart failure pending further confirmation through larger clinical trials. John Wiley and Sons Inc. 2020-07-23 2020-09 /pmc/articles/PMC7520298/ /pubmed/32701210 http://dx.doi.org/10.1111/jcmm.15611 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Mao, Shuai
Liang, Yubin
Chen, Peipei
Zhang, Yuzhuo
Yin, Xin
Zhang, Minzhou
In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title_full In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title_fullStr In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title_full_unstemmed In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title_short In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
title_sort in‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: an exploratory analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520298/
https://www.ncbi.nlm.nih.gov/pubmed/32701210
http://dx.doi.org/10.1111/jcmm.15611
work_keys_str_mv AT maoshuai indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis
AT liangyubin indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis
AT chenpeipei indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis
AT zhangyuzhuo indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis
AT yinxin indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis
AT zhangminzhou indepthproteomicsapproachrevealsnovelbiomarkersofcardiacremodellingaftermyocardialinfarctionanexploratoryanalysis